All In Biotech

Drug Trial Radar · NCT05692180

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

94

Actual

Start

Apr 5, 2023

Primary completion

Dec 23, 2026

Study completion Dec 23, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jan 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.

Conditions

  • Asthma

Interventions

  • BenralizumabDrug

    Benralizumab active solution will be administered SC to the patients.

  • PlaceboDrug

    Placebo solution will be administered SC to the patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first asthma exacerbationTime frame: From Baseline (Week 0) to End of Treatment (EOT) in DB treatment period

Locations

43 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Torrance, California

  • Research Site

    Ocala, Florida

  • Research Site

    Owensboro, Kentucky

  • Research Site

    Lafayette, Louisiana

  • Research Site

    Kansas City, Missouri

  • Research Site

    Northfield, New Jersey

  • Research Site

    The Bronx, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Charleston, South Carolina

  • Research Site

    San Antonio, Texas

  • Research Site

    Tyler, Texas

  • Research Site

    Ciudad de Buenos Aire, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Florida, Argentina

  • Research Site

    Lobos, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Juan Bautista, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Créteil, France

  • Research Site

    Lyon, France

  • Research Site

    Rouen, France

  • Research Site

    Milan, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Bialystok, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Skarżysko-Kamienna, Poland

  • Research Site

    Tarnów, Poland

  • Research Site

    Cheongju-si, South Korea

  • Research Site

    Junggu, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Badalona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Benalmádena, Spain

  • Research Site

    Esplugues de Llobregat, Spain

  • Research Site

    Kaohsiung City, Taiwan

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.